Stock Events

Stock Events

Enlivex 

€0.74
0
+€0.03+3.5% Tuesday 19:32

Statistics

Day High
0.76
Day Low
0.73
52W High
1.5
52W Low
0.61
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

22MayExpected
Q4 2025
Next
-0.12
-0.11
-0.09
-0.07
Expected EPS
-0.07008009600000001
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 1BT.STU. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Mesoblast
MESO
Mkt Cap2.15B
Mesoblast Limited focuses on the development of regenerative medicine, which competes directly with Enlivex's cell therapy approach for inflammatory conditions.
Fate Therapeutics
FATE
Mkt Cap161.61M
Fate Therapeutics is involved in the development of programmed cellular immunotherapies for cancer and immune disorders, directly competing with Enlivex's immunotherapy treatments.
CRISPR Therapeutics
CRSP
Mkt Cap5.57B
CRISPR Therapeutics is a gene editing company that competes in the broader field of genetic and cell therapies, potentially targeting similar diseases as Enlivex.
Novartis
NVS
Mkt Cap293.34B
Novartis AG, through its advanced cell therapy platforms, competes in developing treatments for inflammatory and autoimmune diseases, similar to Enlivex's focus areas.
Gilead Sciences
GILD
Mkt Cap170.84B
Gilead Sciences, with its cell therapy and immunology portfolio, competes in the same therapeutic areas as Enlivex, particularly in treatments for inflammatory and autoimmune diseases.
Allogene Therapeutics
ALLO
Mkt Cap791.75M
Allogene Therapeutics is developing allogeneic CAR T cell therapies, which could compete with Enlivex's cell-based therapies for cancer and immune disorders.
Sangamo Therapeutics
SGMO
Mkt Cap108.54M
Sangamo Therapeutics specializes in genomic medicine, including gene therapy, competing in the innovative treatment space alongside Enlivex.
Biomarin Pharmaceutical
BMRN
Mkt Cap10.51B
BioMarin Pharmaceutical focuses on enzyme replacement therapies and other innovative treatments for rare genetic diseases, competing with Enlivex's focus on severe and life-threatening conditions.

About

Enlivex Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. It offers AllocetraTM, a cell therapy designed to restore macrophage homeostasis, as well as develops AllocetraTM intra-articular injection for the treatment of knee osteoarthritis, which is in phase 1/2 trial; intra-articular AllocetraTM in osteoarthritis of the temporomandibular joint (TMJ); and Allocetra-OTS for the treatment of organ failure in adult sepsis patients, which is in phase 2. Enlivex Ltd. was formerly known as Enlivex Therapeutics Ltd. and changed its name to Enlivex Ltd. in February 2026. The company was founded in 2005 and is headquartered in Ness Ziona, Israel.
Show more...
CEO
Mr. Shai Novik M.B.A.
Employees
34
Country
Israel
ISIN
IL0011319527

Listings

STU
DE
1BT.STU
F
DE
1BT.F
TA
IL
ENLV.TA
XNAS
US
ENLV

0 Comments

Share your thoughts

FAQ

What is Enlivex stock price today?▼
The current price of 1BT.STU is €0.74 EUR — it has increased by +3.5% in the past 24 hours. Watch Enlivex stock price performance more closely on the chart.
What is Enlivex stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Enlivex stocks are traded under the ticker 1BT.STU.
Is Enlivex stock price growing?▼
1BT.STU stock has risen by +7.25% compared to the previous week, the month change is a -15.43% fall, over the last year Enlivex has showed a -5.13% decrease.
When is the next Enlivex earnings date?▼
Enlivex is going to release the next earnings report on May 22, 2026.
What were Enlivex earnings last quarter?▼
1BT.STU earnings for the last quarter are -0.12 EUR per share, whereas the estimation was -0.07 EUR resulting in a -65.24% surprise. The estimated earnings for the next quarter are N/A EUR per share.
How many employees does Enlivex have?▼
As of April 22, 2026, the company has 34 employees.
In which sector is Enlivex located?▼
Enlivex operates in the Health & Wellness sector.
When did Enlivex complete a stock split?▼
Enlivex has not had any recent stock splits.
Where is Enlivex headquartered?▼
Enlivex is headquartered in Ness Ziona, Israel.